BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer
10 Junio 2024 - 8:45AM
BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or
"Company"), a medical technology company delivering unprecedented
accuracy and precision to intra-cardiac signal visualization, today
announced the appointment of Mr. Ferdinand Groenewald to the
position of interim Chief Financial
Officer. Personal Bio, Ferdinand Groenewald, age
39Ferdinand Groenewald is a certified public accountant with
significant experience in finance and accounting. He currently
serves as Vice President, Finance at Alaunos Therapeutics, Inc.
Previously, Mr. Groenewald served as an Independent Outside
Director at SYLA Technologies Co., Ltd.; an Independent Director at
HeartCore Enterprises, Inc.; an Independent Director at Sushi Ginza
Onodera, Inc.; an Accountant at Wrinkle, Gardner & Co. PC; a
Senior Staff Accountant at Financial Consulting Strategies LLC; a
Controller, VP-Finance & Accounting Officer at Sadot Group,
Inc. and a Chief Financial Officer at the same company; and Chief
Accounting Officer & VP-Finance at Muscle Maker Development
LLC. Mr. Groenewald obtained an undergraduate degree from the
University of South Africa.
BioSig’s CEO, Anthony Amato stated, “I am excited to announce
the addition of Ferdinand Groenewald to the evolving team
at BioSig. Mr. Groenewald’s unique financial expertise
will be a key asset to help drive our strategic decisions going
forward. Mr. Groenewald provides a deep understanding of
specific financial principles that will align with our newly
planned broader business strategy. This will play a pivotal role in
shaping growth opportunities to increase shareholder value.”
About BioSig Technologies, Inc. (NASDAQ: BSGM)
BioSig Technologies is a medical technology company focused on
deciphering the body’s electrical signals, starting with heart
rhythms. By leveraging a first of its kind combination of hardware
and software, we deliver unprecedented cardiac signal clarity,
ending the reliance on ‘mixed signals’ and ‘reading between the
lines.’ Our platform technology is addressing some of healthcare’s
biggest challenges—saving time, saving costs, and saving lives.
The Company’s product, the PURE EP™ Platform, an FDA 510(k)
cleared non-invasive class II device, provides superior, real-time
signal visualization allowing physicians to perform highly targeted
cardiac ablation procedures with increased procedural efficiency
and efficacy.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of
future performance, are based on certain assumptions, and are
subject to various known and unknown risks and uncertainties, many
of which are beyond the Company's control, and cannot be predicted
or quantified and consequently, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without
limitation, risks and uncertainties associated with (i) BioSig’s
ability to regain compliance with and meet the continued listing
requirements of the Nasdaq Capital Market to maintain listing of
its common stock; (ii) our cost reduction plan and associated
workforce reduction or other cost-saving measures not reaching the
targeted reduction of cash burn by 50%; (iii) the geographic,
social, and economic impact of pandemics or worldwide health issues
on BioSig’s ability to conduct its business and raise capital in
the future when needed; (iv) BioSig’s inability to manufacture its
products and product candidates on a commercial scale on its own,
or in collaboration with third parties; (v) difficulties in
obtaining financing on commercially reasonable terms; (vi) changes
in the size and nature of BioSig’s competition; (vii) loss of one
or more key executives or scientists; and (viii) difficulties in
securing regulatory approval to market BioSig’s products and
product candidates. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause BioSig’s actual results to differ from those contained in
forward-looking statements, see BioSig’s filings with the
Securities and Exchange Commission (“SEC”), including the section
titled “Risk Factors” in BioSig’s Annual Report on Form 10-K, filed
with the SEC on April 16, 2024. Investors and security holders are
urged to read these documents free of charge on the SEC's website
at http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise, except as
required by law.
Todd Adler
BioSig Technologies, Inc.
Investor Relations
tadler@biosigtech.com
203-409-5444 ext. 104
or
Anthony Amato
Chief Executive Officer
aamato@biosigtech.com
203-409-5444 ext. 102
BioSig Technologies (NASDAQ:BSGM)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
BioSig Technologies (NASDAQ:BSGM)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024